Sign in Subscribe
Coronaviruses

Arbutus Biopharma Announces Multiple Abstracts Accepted for Oral and Poster Presentations at EASL 2021 International Liver Congress

Strategic Insights

— 1 min read

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company focused on developing a cure for chronic hepatitis B virus (HBV) infection, has announced that five abstracts have been accepted for presentation at the upcoming International Liver Congress (ILC), the Annual Meeting of the European Association for the Study of the Liver (EASL) in June 2021. The presentations will cover various aspects of Arbutus' product candidates, including AB-729 and AB-836, which are being developed to treat chronic HBV infection.

Key Takeaways:

  • Arbutus has submitted five abstracts for presentation at the upcoming ILC, covering various aspects of its product candidates, including AB-729 and AB-836.
  • AB-729 is an RNA interference (RNAi) therapeutic that inhibits viral replication and reduces all HBV antigens, including hepatitis B surface antigen.
  • AB-729 has demonstrated positive safety and tolerability data and meaningful reductions in hepatitis B surface antigen in an ongoing single- and multi-dose Phase 1a/1b clinical trial.
  • AB-836 is an oral HBV capsid inhibitor that targets the HBV core protein and prevents the assembly of functional viral capsids.
  • The accepted abstracts include two oral presentations and three poster presentations, covering topics such as HBsAg suppression, preclinical antiviral profile of AB-836, and HBV-specific T cell activation markers.
  • The presentations will feature experts in the field, including Prof. Man-Fung Yuen and Dr. Nagraj Mani, who will discuss the latest research and findings related to Arbutus' product candidates.

Statistics:

  • 250 million people worldwide suffer from chronic HBV infection (Source: World Health Organization estimate).
  • 2 million people in the United States suffer from chronic HBV infection (Source: estimated).
  • 900,000 people die every year from complications related to chronic HBV infection (Source: World Health Organization estimate).
  • 1 in 3 individuals worldwide have been infected with HBV at some point in their lives (Source: World Health Organization estimate).
  • 1 in 100 individuals will develop chronic HBV infection (Source: World Health Organization estimate).

Sources:

  • GlobeNewswire
  • Arbutus Biopharma Corporation press release
  • World Health Organization: Hepatitis B
  • European Association for the Study of the Liver (EASL)
  • International Liver Congress (ILC)
  • ClinicalTrials.gov
  • National Institutes of Health (NIH)

Read more